Severe forms of acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy.

Posology

Ruatine should only be prescribed by or under the supervision of physicians with expertise in the use of systemic retinoids for the treatment of severe acne and a full understanding of the risks of Ruatine therapy and monitoring requirements.

The capsules should be taken with food once or twice daily.

Adults including adolescents and the elderly:

Ruatine therapy should be started at a dose of 0.5 mg/kg daily. The therapeutic response to Ruatine and some of the adverse effects are dose-related and vary between patients. This necessitates individual dosage adjustment during therapy. For most patients, the dose ranges from 0.5-1.0 mg/kg per day.

Long-term remission and relapse rates are more closely related to the total dose administered than to either duration of treatment or daily dose. It has been shown that no substantial additional benefit is to be expected beyond a cumulative treatment dose of 120-150 mg/kg. The duration of treatment will depend on the individual daily dose. A treatment course of 16-24 weeks is normally sufficient to achieve remission.

In the majority of patients, complete clearing of the acne is obtained with a single treatment course. In the event of a definite relapse a further course of Ruatine therapy may be considered using the same daily dose and cumulative treatment dose. As further improvement of the acne can be observed up to 8 weeks after discontinuation of treatment, a further course of treatment should not be considered until at least this period has elapsed.

Patients with renal impairment

In patients with severe renal insufficiency treatment should be started at a lower dose (e.g. 10 mg/day). The dose should then be increased up to 1 mg/kg/day or until the patient is receiving the maximum tolerated dose (see section 4.4).

Paediatric population

Ruatine is not indicated for the treatment of prepubertal acne and is not recommended in patients less than 12 years of age due to a lack of data on efficacy and safety.

Patients with intolerance

In patients who show severe intolerance to the recommended dose, treatment may be continued at a lower dose with the consequences of a longer therapy duration and a higher risk of relapse. In order to achieve the maximum possible efficacy in these patients the dose should normally be continued at the highest tolerated dose.

Method of administration

Oral use.

Ruatine is contraindicated in women who are pregnant or breast-feeding (see section 4.6). Ruatine is contraindicated in women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see section 4.4). Ruatine is also contraindicated in patients • With hepatic insufficiency • With excessively elevated blood lipid values • With hypervitaminosis A • With hypersensitivity to isotretinoin or to any of the excipients • Receiving concomitant treatment with tetracyclines (see section 4.5) • Allergic to peanut or soya oil as isotretinoin contains soya-bean oil

Pregnancy Prevention Programme

This medicinal product is TERATOGENIC

Ruatine is contraindicated in women of childbearing potential unless all of the following conditions of the Pregnancy Prevention Programme are met:

• She has severe acne (such as nodular or conglobate acne or acne at risk of permanent scarring) resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy (see section 4.1).

• She understands the teratogenic risk.

• She understands the need for rigorous follow-up, on a monthly basis.

• She understands and accepts the need for effective contraception, without interruption, 1 month before starting treatment, throughout the duration of treatment and 1 month after the end of treatment. At least one and preferably two complementary forms of contraception including a barrier method should be used.

• Even if she has amenorrhoea she must follow all of the advice on effective contraception.

• She should be capable of complying with effective contraceptive measures.

• She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy.

• She understands the need and accepts to undergo pregnancy testing before, during and 5 weeks after the end of treatment.

• She has acknowledged that she has understood the hazards and necessary precautions associated with the use of Ruatine.

These conditions also concern women who are not currently sexually active unless the prescriber considers that there are compelling reasons to indicate that there is no risk of pregnancy.

The prescriber must ensure that:

• The patient complies with the conditions for pregnancy prevention as listed above, including confirmation that she has an adequate level of understanding.

• The patient has acknowledged the aforementioned conditions.

• The patient has used at least one and preferably two methods of effective contraception including a barrier method for at least 1 month prior to starting treatment and is continuing to use effective contraception throughout the treatment period and for at least 1 month after cessation of treatment.

• Negative pregnancy test results have been obtained before, during and 5 weeks after the end of treatment. The dates and results of pregnancy tests should be documented.

Contraception

Female patients must be provided with comprehensive information on pregnancy prevention and should be referred for contraceptive advice if they are not using effective contraception.

As a minimum requirement, female patients at potential risk of pregnancy must use at least one effective method of contraception. Preferably the patient should use two complementary forms of contraception including a barrier method. Contraception should be continued for at least 1 month after stopping treatment with Ruatine, even in patients with amenorrhoea.

Pregnancy testing

According to local practice medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL are recommended to be performed in the first 3 days of the menstrual cycle, as follows.

Prior to starting therapy:

In order to exclude the possibility of pregnancy prior to starting contraception, it is recommended that an initial medically supervised pregnancy test should be performed and its date and result recorded. In patients without regular menses, the timing of this pregnancy test should reflect the sexual activity of the patient and should be undertaken approximately 3 weeks after the patient last had unprotected sexual intercourse. The prescriber should educate the patient about contraception.

A medically supervised pregnancy test should also be performed during the consultation when Ruatine is prescribed or in the 3 days prior to the visit to the prescriber, and should have been delayed until the patient had been using effective contraception for at least 1 month. This test should ensure the patient is not pregnant when she starts treatment with Ruatine.

Follow-up visits

Follow-up visits should be arranged at 28 day intervals. The need for repeated medically supervised pregnancy tests every month should be determined according to local practice including consideration of the patient's sexual activity and recent menstrual history (abnormal menses, missed periods or amenorrhoea). Where indicated, follow-up pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.

End of treatment

Five weeks after stopping treatment, women should undergo a final pregnancy test to exclude pregnancy.

Prescribing and dispensing restrictions

Prescriptions of Ruatine for women of childbearing potential should be limited to 30 days of treatment and continuation of treatment requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing of Ruatine should occur on the same day. Dispensing of Ruatine should occur within a maximum of 7 days of the prescription.

Male patients

The available data suggest that the level of maternal exposure from the semen of the patients receiving Ruatine, is not of a sufficient magnitude to be associated with the teratogenic effects of Ruatine.

Male patients should be reminded that they must not share their medication with anyone, particularly not females.

Additional precautions

Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.

Patients should not donate blood during therapy and for 1 month following discontinuation of Ruatine because of the potential risk to the fetus of a pregnant transfusion recipient.

Educational material

In order to assist prescribers, pharmacists and patients in avoiding fetal exposure to Ruatine the Marketing Authorisation Holder will provide educational material to reinforce the warnings about the teratogenicity of Ruatine, to provide advice on contraception before therapy is started and to provide guidance on the need for pregnancy testing.

Full patient information about the teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme should be given by the physician to all patients, both male and female.

Psychiatric disorders

Depression including aggravation of pre-existing depression, anxiety, aggressive tendencies, mood alterations, psychotic symptoms and, very rarely, suicidal ideation, suicide attempts and suicide have been reported in patients treated with Ruatine (see section 4.8). Particular care needs to be taken in patients with a history of depression and all patients should be monitored for signs of depression and referred for appropriate treatment if necessary. However, discontinuation of Ruatine may be insufficient to alleviate symptoms and therefore further psychiatric or psychological evaluation may be necessary.

Skin and subcutaneous tissues disorders

Acute exacerbation of acne is occasionally seen during the initial period but this subsides with continued treatment, usually within 7-10 days, and usually does not require dose adjustment.

Exposure to intense sunlight or to UV rays should be avoided. Where necessary a sun-protection product with a high protection factor of at least SPF 15 should be used.

Aggressive chemical dermabrasion and cutaneous laser treatment should be avoided in patients on Ruatine for a period of 5-6 months after the end of the treatment because of the risk of hypertrophic scarring in atypical areas and more rarely post inflammatory hyper or hypopigmentation in treated areas. Wax depilation should be avoided in patients on Ruatine for at least a period of 6 months after treatment because of the risk of epidermal stripping.

Concurrent administration of Ruatine with topical keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase (see section 4.5).

Patients should be advised to use a skin moisturising ointment or cream and a lip balm from the start of treatment as Ruatine is likely to cause dryness of the skin and lips.

There have been post-marketing reports of severe skin reactions (e.g. erythema multiforme (EM), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)) associated with Ruatine use. As these events may be difficult to distinguish from other skin reactions that may occur (see section 4.8), patients should be advised of the signs and symptoms and monitored closely for severe skin reactions. If a severe skin reaction is suspected, Ruatine treatment should be discontinued.

Allergic reactions

Anaphylactic reactions have been rarely reported, in some cases after previous topical exposure to retinoids. Allergic cutaneous reactions are reported infrequently. Serious cases of allergic vasculitis, often with purpura (bruises and red patches) of the extremities and extracutaneous involvement have been reported. Severe allergic reactions necessitate interruption of therapy and careful monitoring.

Eye disorders

Dry eyes, corneal opacities, decreased night vision and keratitis usually resolve after discontinuation of therapy. Dry eyes can be helped by the application of a lubricating eye ointment or by the application of tear replacement therapy. Intolerance to contact lenses may occur which may necessitate the patient to wear glasses during treatment.

Decreased night vision has also been reported and the onset in some patients was sudden (see section 4.7). Patients experiencing visual difficulties should be referred for an expert ophthalmological opinion. Withdrawal of Ruatine may be necessary.

Musculo-skeletal and connective tissue disorders

Myalgia, arthralgia and increased serum creatine phosphokinase values have been reported in patients receiving Ruatine, particularly in those undertaking vigorous physical activity (see section 4.8). In some cases, this may progress to potentially life threatening rhabdomyolysis.

Bone changes including premature epiphyseal closure, hyperostosis, and calcification of tendons and ligaments have occurred after several years of administration at very high doses for treating disorders of keratinisation. The dose levels, duration of treatment and total cumulative dose in these patients generally far exceeded those recommended for the treatment of acne.

Benign intracranial hypertension

Cases of benign intracranial hypertension have been reported, some of which involved concomitant use of tetracyclines (see sections 4.3 and 4.5). Signs and symptoms of benign intracranial hypertension include headache, nausea and vomiting, visual disturbances and papilloedema. Patients who develop benign intracranial hypertension should discontinue Ruatine immediately.

Hepatobiliary disorders

Liver enzymes should be checked before treatment, 1 month after the start of treatment, and subsequently at 3 monthly intervals unless more frequent monitoring is clinically indicated. Transient and reversible increases in liver transaminases have been reported. In many cases these changes have been within the normal range and values have returned to baseline levels during treatment. However, in the event of persistent clinically relevant elevation of transaminase levels, reduction of the dose or discontinuation of treatment should be considered.

Renal insufficiency

Renal insufficiency and renal failure do not affect the pharmacokinetics of Ruatine. Therefore, Ruatine can be given to patients with renal insufficiency. However, it is recommended that patients are started on a low dose and titrated up to the maximum tolerated dose (see section 4.2).

Lipid Metabolism

Serum lipids (fasting values) should be checked before treatment, 1 month after the start of treatment, and subsequently at 3 monthly intervals unless more frequent monitoring is clinically indicated. Elevated serum lipid values usually return to normal on reduction of the dose or discontinuation of treatment and may also respond to dietary measures.

Ruatine has been associated with an increase in plasma triglyceride levels. Ruatine should be discontinued if hypertriglyceridaemia cannot be controlled at an acceptable level or if symptoms of pancreatitis occur (see section 4.8). Levels in excess of 800 mg/dL or 9 mmol/L are sometimes associated with acute pancreatitis, which may be fatal.

Gastrointestinal disorders

Ruatine has been associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. Patients experiencing severe (haemorrhagic) diarrhoea should discontinue Ruatine immediately.

High risk patients

In patients with diabetes, obesity, alcoholism or a lipid metabolism disorder undergoing treatment with Ruatine, more frequent checks of serum values for lipids and/or blood glucose may be necessary. Elevated fasting blood sugars have been reported, and new cases of diabetes have been diagnosed during Ruatine therapy.

Patients should not take vitamin A as concurrent medication due to the risk of developing hypervitaminosis A.

Cases of benign intracranial hypertension (pseudotumour cerebri) have been reported with concomitant use of Ruatine and tetracyclines. Therefore, concomitant treatment with tetracyclines must be avoided (see section 4.3 and section 4.4).

Concurrent administration of Ruatine with topical keratolytic or exfoliative anti-acne agents should be avoided as local irritation may increase (see section 4.4).

Pregnancy

Pregnancy is an absolute contraindication to treatment with Ruatine (see section 4.3). Women of childbearing potential have to use effective contraception during and up to one month after treatment. If pregnancy does occur in spite of these precautions during treatment with Ruatine or in the month following, there is a great risk of very severe and serious malformation of the fetus

The fetal malformations associated with exposure to Ruatine include central nervous system abnormalities (hydrocephalus, cerebellar malformation/abnormalities, microcephaly), facial dysmorphia, cleft palate, external ear abnormalities (absence of external ear, small or absent external auditory canals), eye abnormalities (microphthalmia), cardiovascular abnormalities (conotruncal malformations such as tetralogy of Fallot, transposition of great vessels, septal defects), thymus gland abnormality and parathyroid gland abnormalities. There is also an increased incidence of spontaneous abortion.

If pregnancy occurs in a woman treated with Ruatine, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.

Breast-feedingRuatine is highly lipophilic, therefore the passage of Ruatine into human milk is very likely. Due to the potential for adverse effects in the child exposed via mothers' milk, Ruatine is contraindicated during breast-feeding (see section 4.3).

Fertility

Ruatine, in therapeutic dosages, does not affect the number, motility and morphology of sperm and does not jeopardise the formation and development of the embryo on the part of the men taking Ruatine.

Ruatine could potentially have an influence on the ability to drive and use machines.

A number of cases of decreased night vision have occurred during Ruatine therapy and in rare instances have persisted after therapy (see section 4.4 and section 4.8). Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating machines.

Drowsiness, dizziness and visual disturbances have been reported very rarely. Patients should be warned that if they experience these effects, they should not drive, operate machinery or take part in any other activities where the symptoms could put either themselves or others at risk.

Summary of safety profile

Some of the side effects associated with the use of Ruatine are dose-related. The side effects are generally reversible after altering the dose or discontinuation of treatment, however some may persist after treatment has stopped. The following symptoms are the most commonly reported undesirable effects with Ruatine: dryness of the mucosae e.g. of the lips (cheilitis), the nasal mucosa (epistaxis), and the eyes (conjunctivitis), dryness of the skin.

Tabulated list of adverse reactions

The incidence of the adverse reactions calculated from pooled clinical trial data involving 824 patients and from postmarketing data are presented in the table below. The adverse reactions are listed below by MedDRA system organ class (SOC) and categories of frequency. Frequency categories are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (≥1/10,000 to <1/1,000) and not known (cannot be estimated from the available data). Within each frequency grouping and SOC, adverse reactions are presented in order of decreasing seriousness.

Table 1 Tabulated list of adverse reactions in patients treated with Ruatine

System Organ Class	Very Common	Common	Rare	Very Rare	Not Known
Infections and infestations:				Gram positive (mucocutaneous) bacterial infection
Blood and lymphatic system disorders:	Anaemia, Red blood cell sedimentation rate increased, Thrombocytopenia, Thrombocytosis	Neutropenia		Lymphadenopathy
Immune system disorders:			Allergic skin reaction, Anaphylactic reactions, Hypersensitivity
Metabolism and nutrition disorders:				Diabetes mellitus, Hyperuricaemia
Psychiatric disorders:			Depression including aggravation of pre-existing depression, Aggressive tendencies, Anxiety, Mood Alterations	Abnormal behaviour, Psychotic disorder, Suicidal ideation, Suicide attempt, Suicide
Nervous system disorders:		Headache		Benign intracranial hypertension, Convulsions, Drowsiness, Dizziness
Eye disorders:	Blepharitis, Conjunctivitis, Dry eye, Eye irritation			Blurred vision, Cataract, Colour blindness (colour vision deficiencies), Contact lens intolerance, Corneal opacity, Decreased night vision, Keratitis, Papilloedema (as sign of benign intracranial hypertension), Photophobia, Visual disturbances
Ear and labyrinth disorders:				Hearing impaired
Vascular disorders:				Vasculitis (for example Wegener's granulomatosis, allergic vasculitis)
Respiratory, thoracic and mediastinal disorders:		Epistaxis, Nasal dryness, Nasopharyngitis		Bronchospasm (particularly in patients with asthma), Hoarseness
Gastrointestinal disorders:				Colitis, Ileitis, Dry throat, Gastrointestinal haemorrhage, haemorrhagic diarrhoea and inflammatory bowel disease, Nausea, Pancreatitis (see section 4.4)
Hepatobiliary disorders:	Transaminase increased (see section 4.4)			Hepatitis
Skin and subcutaneous tissues disorders:	Cheilitis, Dermatitis, Dry skin, Localised exfoliation, Pruritus, Rash erythematous, Skin fragility (and risk of frictional trauma)		Alopecia	Acne fulminans, Acne aggravated (acne flare), Erythema (facial), Exanthema, Hair disorders, Hirsutism, Nail dystrophy, Paronychia, Photosensitivity reaction, Pyogenic granuloma, Skin hyperpigmentation, Sweating increased	Erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis.
Musculoskeletal and connective tissue disorders:	Arthralgia, Myalgia, Back pain (particularly in children and adolescent patients)			Arthritis, Calcinosis (calcification of ligaments and tendons), Epiphyses premature fusion, Exostosis, (hyperostosis), Reduced bone density, Tendonitis, Rhabdomyolysis
Renal and urinary disorders:				Glomerulonephritis
Reproductive system and breast disorders					Sexual dysfunction including erectile dysfunction and decreased libido
General disorders and administration site conditions:				Granulation tissue (increased formation of), Malaise
Investigations:	Blood triglycerides increased, High density lipoprotein decreased	Blood cholesterol increased, Blood glucose increased, Haematuria, Proteinuria		Blood creatine phosphokinase increased

 

e. To reports any side effect(s):

·       Saudi Arabia:

- The National Pharmacovigilance and Drug Safety Centre (NPC) :

·       Fax: +966-11-205-7662

·       Call NPC at +966-11-2038222

·       Toll free phone: 8002490000

·       E-mail: npc.drug@sfda.gov.sa

·       Website: www.sfda.gov.sa

·       Website: www.sfda.gov.sa/npc

 

Isotretinoin is a derivative of vitamin A. Although the acute toxicity of isotretinoin is low, signs of hypervitaminosis A could appear in cases of accidental overdose. Manifestations of acute vitamin A toxicity include severe headache, nausea or vomiting, drowsiness, irritability and pruritus. Signs and symptoms of accidental or deliberate overdosage with Ruatine would probably be similar. These symptoms would be expected to be reversible and to subside without the need for treatment.

Pharmacotherapeutic group: Retinoid for the treatment of acne, ATC code: D10BA01

Mechanism of action

Ruatine is a stereoisomer of all-trans retinoic acid (tretinoin). The exact mechanism of action of Ruatine has not yet been elucidated in detail, but it has been established that the improvement observed in the clinical picture of severe acne is associated with suppression of sebaceous gland activity and a histologically demonstrated reduction in the size of the sebaceous glands. Furthermore, a dermal anti-inflammatory effect of Ruatine has been established.

Clinical efficacy and safety

Hypercornification of the epithelial lining of the pilosebaceous unit leads to shedding of corneocytes into the duct and blockage by keratin and excess sebum. This is followed by formation of a comedone and, eventually, inflammatory lesions. Ruatine inhibits proliferation of sebocytes and appears to act in acne by re-setting the orderly programme of differentiation. Sebum is a major substrate for the growth of Propionibacterium acnes so that reduced sebum production inhibits bacterial colonisation of the duct.

Absorption

The absorption of Ruatine from the gastro-intestinal tract is variable and dose-linear over the therapeutic range. The absolute bioavailability of Ruatine has not been determined, since the compound is not available as an intravenous preparation for human use, but extrapolation from dog studies would suggest a fairly low and variable systemic bioavailability. When Ruatine is taken with food, the bioavailability is doubled relative to fasting conditions.

Distribution

Ruatine is extensively bound to plasma proteins, mainly albumin (99.9%). The volume of distribution of Ruatine in man has not been determined since Ruatine is not available as an intravenous preparation for human use. In humans little information is available on the distribution of Ruatine into tissue. Concentrations of Ruatine in the epidermis are only half of those in serum. Plasma concentrations of Ruatine are about 1.7 times those of whole blood due to poor penetration of Ruatine into red blood cells.

Biotransformation

After oral administration of Ruatine, three major metabolites have been identified in plasma: 4-oxo-Ruatine, tretinoin (all-trans retinoic acid), and 4-oxo-tretinoin. These metabolites have shown biological activity in several in vitro tests. 4-oxo-Ruatine has been shown in a clinical study to be a significant contributor to the activity of Ruatine (reduction in sebum excretion rate despite no effect on plasma levels of Ruatine and tretinoin). Other minor metabolites include glucuronide conjugates. The major metabolite is 4-oxo-Ruatine with plasma concentrations at steady state that are 2.5 times higher than those of the parent compound.

isotretinoin and tretinoin (all-trans retinoic acid) are reversibly metabolised (interconverted), and the metabolism of tretinoin is therefore linked with that of isotretinoin. It has been estimated that 20-30% of an isotretinoin dose is metabolised by isomerisation.

Enterohepatic circulation may play a significant role in the pharmacokinetics of isotretinoin in man. In vitro metabolism studies have demonstrated that several CYP enzymes are involved in the metabolism of isotretinoin to 4-oxo-isotretinoin and tretinoin. No single isoform appears to have a predominant role. Isotretinoin and its metabolites do not significantly affect CYP activity.

Elimination

After oral administration of radiolabelled isotretinoin approximately equal fractions of the dose were recovered in urine and faeces. Following oral administration of isotretinoin, the terminal elimination half-life of unchanged drug in patients with acne has a mean value of 19 hours. The terminal elimination half-life of 4-oxo-isotretinoin is longer, with a mean value of 29 hours.

Isotretinoin is a physiological retinoid and endogenous retinoid concentrations are reached within approximately two weeks following the end of isotretinoin therapy.

Hepatic impairment

Since isotretinoin is contraindicated in patients with hepatic impairment, limited information on the kinetics of isotretinoin is available in this patient population.

Renal impairment

Renal failure does not significantly reduce the plasma clearance of isotretinoin or 4-oxo-isotretinoin.

Acute toxicity

The acute oral toxicity of isotretinoin was determined in various animal species. LD50 is approximately 2000 mg/kg in rabbits, approximately 3000 mg/kg in mice, and over 4000 mg/kg in rats.

Chronic toxicity

A long-term study in rats over 2 years (isotretinoin dosage 2, 8 and 32 mg/kg/d) produced evidence of partial hair loss and elevated plasma triglycerides in the higher dose groups. The side effect spectrum of isotretinoin in the rodent thus closely resembles that of vitamin A, but does not include the massive tissue and organ calcifications observed with vitamin A in the rat. The liver cell changes observed with vitamin A did not occur with Ruatine.

All observed side effects of hypervitaminosis A syndrome were spontaneously reversible after withdrawal of Ruatine. Even experimental animals in a poor general state had largely recovered within 1-2 weeks.

Teratogenicity

Like other vitamin A derivatives, isotretinoin has been shown in animal experiments to be teratogenic and embryotoxic.

Due to the teratogenic potential of Ruatine there are therapeutic consequences for the administration to women of a childbearing age (see section 4.3, section 4.4 and section 4.6).

Mutagenicity

Ruatine has not been shown to be mutagenic nor carcinogenic in in vitro or in vivo animal tests respectively.

Capsule contents

Soya-bean oil,

Hydrogenated Soya bean

Di Sodium Edetate

Butylated Hydroxy Anisol

Capsule shell

Glycerin

Gelatin 150 bloom

,Propyl Paraben

Red # 33 lake

Methyl Paraben

Titanium dioxide

Not applicable.

2 Years.

Do not store above 30°C.

Store in the original container. Keep the container tightly closed to protect from light.

RUATINE® are packed in blisters of Aluminum / Aluminum foil, in carton box with a multi folded leaflet.

Pack size: 30 soft gelatin capsule; (10 soft gelatin capsule /blister, 3 blisters/ pack).

No special Instructions.